Foghorn Therapeutics
Yunji Davenport is a highly experienced scientist in the field of drug discovery, currently serving as Director at Foghorn Therapeutics, Inc., where a progressive career since November 2017 has included roles as Principal Scientist, Senior Scientist, and Scientist. Prior to this, Yunji completed a Jane Coffin Childs Postdoctoral Fellowship at Harvard Medical School under the guidance of Dr. Jon Clardy from September 2015 to November 2017. Education includes a Ph.D. in Biochemistry and Molecular Biology from the California Institute of Technology, where Yunji also worked as a Graduate Research Assistant and Teaching Assistant, as well as a Bachelor of Science in Chemistry from the Massachusetts Institute of Technology. Early career experience includes a research assistantship at MIT and an internship at Biogen Idec in the Department of Physical Biochemistry.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.